logo

CORONA vs FISCHER: Stock Comparison

CORONA REMEDIES vs FISCHER MEDICAL VENTURE LUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a higher ROE, a higher dividend yield and a higher ROCE, while FISCHER MEDICAL VENTURE L shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CORONA leads 5; FISCHER leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CORONAFISCHER

Valuation lens

What price are you paying?

Market CapContext only
₹12,313 Cr
₹1,846 Cr
P/E RatioFISCHER has the lower reading
61.87x
61.33x ✓
P/B RatioFISCHER has the lower reading
16.49x
4.81x ✓
EPSCORONA has the higher reading
₹9.83 ✓
₹0.06
Book ValueContext only
₹122.12
₹5.88
Dividend YieldCORONA has the higher reading
0.5% ✓
0.18%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CORONA is the larger company
₹12,313 Cr vs ₹1,846 Cr
P/E Ratio
FISCHER has a lower P/E
61.33x vs 61.87x
P/B Ratio
FISCHER has a lower P/B
4.81x vs 16.49x
EPS
CORONA has higher earnings per share
₹9.83 vs ₹0.06
Dividend Yield
CORONA has a higher dividend yield
0.5% vs 0.18%
Revenue Growth (TTM YoY)
FISCHER has faster revenue growth
98.7% vs 0%
ROE
CORONA has a higher ROE
24.28% vs 8.05%
ROCE
CORONA has a higher ROCE
20.94% vs 7.89%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCORONAFISCHER
Sector—Healthcare
Industry—Medical Equipment & Supplies

Price

MetricCORONAFISCHER
Live Price₹2,010₹28.27
Day Change0.3%-4.69%
Volume17,4444.1 L
52-Week High₹2,292.4₹121.7
52-Week Low₹1,336.6₹29.11
Distance from 52W High-12.32%-76.77%

Valuation

MetricCORONAFISCHER
Market Cap₹12,313 Cr₹1,846 Cr
P/E Ratio61.87x61.33x
P/B Ratio16.49x4.81x
EPS₹9.83₹0.06
Book Value₹122.12₹5.88
Dividend Yield0.5%0.18%

Growth

MetricCORONAFISCHER
Revenue Growth (TTM YoY)0%98.7%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricCORONAFISCHER
ROE24.28%8.05%
ROCE20.94%7.89%
Net Margin13.19%6.79%
Operating Margin15.89%16.99%
Debt to Equity0.19x0.19x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricCORONAFISCHER
Promoter Holding69%12.31%▲ 0.85 pp
FII Holding4.21%▲ 0.58 pp5.57%▲ 0.09 pp
DII Holding16.45%▲ 3.55 pp1.26%▼ 0.09 pp
Public Holding10.34%▼ 4.14 pp30.09%▼ 0.93 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and FISCHER MEDICAL VENTURE L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.